


 NASDAQ: TNXP

 HQ: Chatham, NJ

 \$145.5M of Cash
As of 6/30/22

 investor.relations@
tonixpharma.com

MANAGEMENT TEAM

Seth Lederman, MD
Co-Founder, CEO & Chairman

Gregory Sullivan, MD
Chief Medical Officer

Bradley Saenger, CPA
Chief Financial Officer

Jessica Morris
Chief Operating Officer

MAIN U.S. OFFICES

New Jersey Office
(Corporate Headquarters)
26 Main Street - Ste 101
Chatham, NJ 07928

New York Office
509 Madison Ave. - Ste 1608
New York, NY 10022

Research and Development
Center (RDC)
431 Aviation Way
Frederick, MD 21701

Advanced Development
Center (ADC)
259 Samuel Barnet Blvd
New Bedford Business Park
North Dartmouth, MA 02745

www.tonixpharma.com
@TonixPharma

What We Do

Our mission is to advance the science and understanding of diseases by developing **innovative therapies** that have the potential to address **unmet needs**.

Leveraging the **expertise of the Company's leaders**, Tonix's strategy includes:

- Development of a diverse yet curated portfolio, including small molecule drugs and biologics, across a range of therapeutic areas
- Investment in domestic, in-house, R&D and manufacturing to accelerate development timelines and improve the ability to respond to pandemics
- Partnering strategically with other biotech companies, world-class academic and non-profit research organizations to bring innovative therapeutics to market faster

Therapeutic Areas

Central Nervous System

Tonix is dedicated to finding treatments for difficult-to-treat, widely occurring, chronic disorders of the central nervous system including pain, neurologic, psychiatric and addiction conditions, using non-opioid, non-addictive therapies.

Immunology

Tonix is advancing scientific programs that focus on therapeutics to prevent organ transplant rejection, to manage autoimmune conditions, and to improve responses to immunotherapy in certain cancers.

Infectious Disease

Tonix is targeting pathogenic infections, including the ongoing COVID-19 pandemic. Tonix is attacking COVID-19 by developing vaccines, antivirals and a Long COVID therapeutic. Pandemic preparedness is necessary to combat infections like SARS-CoV-2.

Rare Disease

Tonix is developing novel therapies for patients with rare diseases, including those caused by genetic disorders which are characterized by complex symptoms and for which no drug is approved.

Development Pipeline: Key Product Candidates

Using our integrated development engine, we advance innovative programs into the clinic

Central Nervous System

| | Status | Small Molecule | Biologic / Small Peptide | Monoclonal Antibody (mAb) |
|--------------------------------------------------------------------------------------------|---------------|----------------|--------------------------|---------------------------|
| TNX-102 SL Fibromyalgia (FM) Confirmatory Phase 3: initiated 2Q 2022 | Mid-Phase 3 | + | | |
| TNX-102 SL Posttraumatic Stress Disorder (PTSD) Phase 2 start: targeting 3Q 2022 | Phase 2 ready | + | | |
| TNX-102 SL Long COVID Phase 2 start: targeting 3Q 2022 | Phase 2 ready | + | | |
| TNX-1300 Cocaine Intoxication/Overdose Breakthrough Therapy Designation | Mid-Phase 2 | | + | |
| TNX-1900 Chronic Migraine Phase 2 start: targeting 1H 2023 | Phase 2 ready | | + | |

Immunology

| | Status | Small Molecule | Biologic / Small Peptide | Monoclonal Antibody (mAb) |
|-----------------------------------------------------------------------------------------------------|-------------|----------------|--------------------------|---------------------------|
| TNX-1500 Organ Transplant Rejection/Autoimmune Disorders Phase 1 start: targeting 1H 2023 | Preclinical | | | + |
| TNX-1700 Gastric and Colorectal Cancers | Preclinical | | + | |

Infectious Disease

| | Status | Small Molecule | Biologic / Small Peptide | Monoclonal Antibody (mAb) |
|-----------------------------------------------------------------------------------|-------------|----------------|--------------------------|---------------------------|
| TNX-1850 COVID-19 Vaccine Phase 1 start: targeting 2H 2023 | Preclinical | | + | |
| TNX-3600 COVID-19 Therapeutic | Preclinical | | | + |
| TNX-801 Smallpox and Monkeypox Vaccine Phase 1 start: targeting 1H 2023 | Preclinical | | + | |

Rare Disease

| | Status | Small Molecule | Biologic / Small Peptide | Monoclonal Antibody (mAb) |
|------------------------------------------------------------------|-------------|----------------|--------------------------|---------------------------|
| TNX-2900 Prader-Willi Syndrome Orphan Drug Designation | Preclinical | | + | |

*All of Tonix's product candidates are investigational new drugs or biologics and have not been approved for any indication. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. We cannot predict whether the global COVID-19 pandemic will impact the timing of these milestones.

Our Facilities

We are building out our internal R&D and manufacturing capabilities in the US

| | Research and Development Center (RDC) | Advanced Development Center (ADC) | Commercial Manufacturing Center (CMC) |
|--------------------|------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|-------------------------------------------------------------------|
| Function | Accelerated development of vaccines and antiviral drugs for COVID-19, its variants and other infectious diseases | Development and clinical scale manufacturing of live-virus vaccines | Phase 3 and Commercial scale manufacturing of live-virus vaccines |
| Description | ~48,000 square feet, BSL-2 with some areas designated BSL-3 | ~45,000 square feet, BSL-2 | ~44 acre green field site, planned BSL-2 |
| Status | Operational | Partially operational as of 2Q 2022 | Planning for site enabling work in 2022 |
| Location | Frederick, Maryland | North Dartmouth, Massachusetts | Hamilton, Montana |

